Detalhe da pesquisa
1.
Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors.
Bioorg Chem
; 98: 103689, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32171993
2.
Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.
J Med Chem
; 62(24): 11135-11150, 2019 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31721578
3.
Design and synthesis of BPR1K653 derivatives targeting the back pocket of Aurora kinases for selective isoform inhibition.
Eur J Med Chem
; 151: 533-545, 2018 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29656197
4.
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.
J Med Chem
; 61(3): 818-833, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29314840
5.
Design, Synthesis, and Evaluation of Thiazolidine-2,4-dione Derivatives as a Novel Class of Glutaminase Inhibitors.
J Med Chem
; 60(13): 5599-5612, 2017 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28609101
6.
Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design.
Eur J Med Chem
; 124: 186-199, 2016 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-27573544
7.
Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation.
Oncotarget
; 7(52): 86239-86256, 2016 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-27863392
8.
Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
Eur J Med Chem
; 100: 151-61, 2015 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26081023
9.
Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor.
J Med Chem
; 56(13): 5247-60, 2013 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23808327
10.
Discovery of 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a novel peripherally restricted cannabinoid-1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice.
J Med Chem
; 56(24): 9920-33, 2013 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24224693
11.
Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist.
ChemMedChem
; 5(9): 1439-43, 2010 Sep 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-20652930